The Minister directed officials to continue to focus on surveillance and on Whole Genome Sequencing to scan for any possible mutation and also directed for monitoring hospitalizations due to COVID-19 and SARI/ILI cases
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition.
Many kids who have heart transplants live a normal, healthy life once they recover from surgery.
Increased and timely testing will enable early identification of COVID cases and help to curb spread of the infection among the community
Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile
Focussed campaigns for old age homes, schools/colleges, prisons, brick kilns to be taken up by States/UTs
Trial will assess safety and antibody responses of NVX-CoV2515 to the Omicron variant of COVID-19
Approval follows CHMP recommendation for use in patients previously vaccinated with Vaxzevria or an EU-approved mRNA Covid-19 vaccine
The vaccine was found to have 64% efficacy against symptomatic disease and 92% against severe Covid-19
Subscribe To Our Newsletter & Stay Updated
